{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:41:36Z","timestamp":1792928496357,"version":"4.5.0"},"reference-count":235,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41569-026-01274-y","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:19:30Z","timestamp":1774027170000},"page":"726-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-5193","authenticated-orcid":false,"given":"Miles J.","family":"De Blasio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-0058","authenticated-orcid":false,"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11154-010-9131-7","volume":"11","author":"S Boudina","year":"2010","unstructured":"Boudina, S. & Abel, E. D. Diabetic cardiomyopathy, causes and effects. Rev. Endocr. Metab. Disord. 11, 31\u201339 (2010).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"1274_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","volume":"61","author":"G Jia","year":"2018","unstructured":"Jia, G., Whaley-Connell, A. & Sowers, J. R. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia 61, 21\u201328 (2018).","journal-title":"Diabetologia"},{"key":"1274_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10741-022-10238-6","volume":"28","author":"A Palazzuoli","year":"2023","unstructured":"Palazzuoli, A. & Iacoviello, M. Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence. Heart Fail. Rev. 28, 585\u2013596 (2023).","journal-title":"Heart Fail. Rev."},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1161\/CIRCULATIONAHA.123.065546","volume":"149","author":"J Zhan","year":"2024","unstructured":"Zhan, J. et al. AGO2 protects against diabetic cardiomyopathy by activating mitochondrial gene translation. Circulation 149, 1102\u20131120 (2024).","journal-title":"Circulation"},{"key":"1274_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158280","volume":"25","author":"S Giardinelli","year":"2024","unstructured":"Giardinelli, S., Meliota, G., Mentino, D., D\u2019Amato, G. & Faienza, M. F. Molecular basis of cardiomyopathies in type 2 diabetes. Int. J. Mol. Sci. 25, 8280 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1274_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","volume":"57","author":"H Bugger","year":"2014","unstructured":"Bugger, H. & Abel, E. D. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57, 660\u2013671 (2014).","journal-title":"Diabetologia"},{"key":"1274_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1210\/er.2003-0012","volume":"25","author":"ZY Fang","year":"2004","unstructured":"Fang, Z. Y., Prins, J. B. & Marwick, T. H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr. Rev. 25, 543\u2013567 (2004).","journal-title":"Endocr. Rev."},{"key":"1274_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","volume":"142","author":"K Huynh","year":"2014","unstructured":"Huynh, K., Bernardo, B. C., McMullen, J. R. & Ritchie, R. H. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol. Ther. 142, 375\u2013415 (2014).","journal-title":"Pharmacol. Ther."},{"key":"1274_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","volume":"126","author":"RH Ritchie","year":"2020","unstructured":"Ritchie, R. H. & Abel, E. D. Basic mechanisms of diabetic heart disease. Circ. Res. 126, 1501\u20131525 (2020).","journal-title":"Circ. Res."},{"key":"1274_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4239\/wjd.v6.i13.1246","volume":"6","author":"BM Leon","year":"2015","unstructured":"Leon, B. M. & Maddox, T. M. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes 6, 1246\u20131258 (2015).","journal-title":"World J. Diabetes"},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1172\/JCI29103","volume":"116","author":"M Prentki","year":"2006","unstructured":"Prentki, M. & Nolan, C. J. Islet beta cell failure in type 2 diabetes. J. Clin. Invest. 116, 1802\u20131812 (2006).","journal-title":"J. Clin. Invest."},{"key":"1274_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia, U. et al. Pathophysiology of type 2 diabetes mellitus. Int. J. Mol. Sci. 21, 6275 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1274_CR14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2337\/diab.23.2.105","volume":"23","author":"MJ Garcia","year":"1974","unstructured":"Garcia, M. J., McNamara, P. M., Gordon, T. & Kannel, W. B. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23, 105\u2013111 (1974).","journal-title":"Diabetes"},{"key":"1274_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel, W. B., Hjortland, M. & Castelli, W. P. Role of diabetes in congestive heart failure: the Framingham study. Am. J. Cardiol. 34, 29\u201334 (1974).","journal-title":"Am. J. Cardiol."},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.59.1.8","volume":"59","author":"WB Kannel","year":"1979","unstructured":"Kannel, W. B. & McGee, D. L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59, 8\u201313 (1979).","journal-title":"Circulation"},{"key":"1274_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick, T. H., Ritchie, R., Shaw, J. E. & Kaye, D. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 71, 339\u2013351 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1274_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler, S. et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30, 595\u2013602 (1972).","journal-title":"Am. J. Cardiol."},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.cardfail.2014.02.007","volume":"20","author":"S Dandamudi","year":"2014","unstructured":"Dandamudi, S. et al. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J. Card. Fail. 20, 304\u2013309 (2014).","journal-title":"J. Card. Fail."},{"key":"1274_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03401-3","volume":"22","author":"I Swiatkiewicz","year":"2024","unstructured":"Swiatkiewicz, I., Patel, N. T., Villarreal-Gonzalez, M. & Taub, P. R. Prevalence of diabetic cardiomyopathy in patients with type 2 diabetes in a large academic medical center. BMC Med. 22, 195 (2024).","journal-title":"BMC Med."},{"key":"1274_CR21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/CS20160491","volume":"131","author":"M Tate","year":"2017","unstructured":"Tate, M., Grieve, D. J. & Ritchie, R. H. Are targeted therapies for diabetic cardiomyopathy on the horizon? Clin. Sci. 131, 897\u2013915 (2017).","journal-title":"Clin. Sci."},{"key":"1274_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/1753-0407.12239","volume":"7","author":"AP Ofstad","year":"2015","unstructured":"Ofstad, A. P. et al. Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: a cross-sectional comparison with non-diabetic weight-matched controls. J. Diabetes 7, 779\u2013790 (2015).","journal-title":"J. Diabetes"},{"key":"1274_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.tcm.2014.09.005","volume":"25","author":"R Mahajan","year":"2015","unstructured":"Mahajan, R., Lau, D. H. & Sanders, P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc. Med. 25, 119\u2013126 (2015).","journal-title":"Trends Cardiovasc. Med."},{"key":"1274_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.freeradbiomed.2015.04.028","volume":"87","author":"MJ De Blasio","year":"2015","unstructured":"De Blasio, M. J. et al. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110\u03b1) signaling. Free Radic. Biol. Med. 87, 137\u2013147 (2015).","journal-title":"Free Radic. Biol. Med."},{"key":"1274_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.00124","volume":"11","author":"MJ De Blasio","year":"2020","unstructured":"De Blasio, M. J. et al. Defining the progression of diabetic cardiomyopathy in a mouse model of type 1 diabetes. Front. Physiol. 11, 124 (2020).","journal-title":"Front. Physiol."},{"key":"1274_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejphar.2017.04.026","volume":"807","author":"MJ De Blasio","year":"2017","unstructured":"De Blasio, M. J. et al. The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy. Eur. J. Pharmacol. 807, 12\u201320 (2017).","journal-title":"Eur. J. Pharmacol."},{"key":"1274_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1042\/CS20170063","volume":"131","author":"D Prakoso","year":"2017","unstructured":"Prakoso, D. et al. Phosphoinositide 3-kinase (p110\u03b1) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin. Sci. 131, 1345\u20131360 (2017).","journal-title":"Clin. Sci."},{"key":"1274_CR28","doi-asserted-by":"publisher","first-page":"H840","DOI":"10.1152\/ajpheart.00632.2019","volume":"318","author":"D Prakoso","year":"2020","unstructured":"Prakoso, D. et al. Enhanced cardiac phosphoinositide 3-kinase (p110\u03b1) using gene therapy attenuates cardiac remodeling in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 318, H840\u2013H852 (2020).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1274_CR29","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/cvr\/cvab043","volume":"118","author":"D Prakoso","year":"2022","unstructured":"Prakoso, D. et al. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. Cardiovasc. Res. 118, 212\u2013225 (2022).","journal-title":"Cardiovasc. Res."},{"key":"1274_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-35680-w","volume":"13","author":"A Sharma","year":"2023","unstructured":"Sharma, A. et al. Cardiovascular characterisation of a novel mouse model that combines hypertension and diabetes co-morbidities. Sci. Rep. 13, 8741 (2023).","journal-title":"Sci. Rep."},{"key":"1274_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.719290","volume":"12","author":"M Tate","year":"2021","unstructured":"Tate, M. et al. Bone morphogenetic protein 7 gene delivery improves cardiac structure and function in a murine model of diabetic cardiomyopathy. Front. Pharmacol. 12, 719290 (2021).","journal-title":"Front. Pharmacol."},{"key":"1274_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01395","volume":"10","author":"M Tate","year":"2019","unstructured":"Tate, M. et al. Characterising an alternative murine model of diabetic cardiomyopathy. Front. Physiol. 10, 1395 (2019).","journal-title":"Front. Physiol."},{"key":"1274_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","volume":"45","author":"MA Matter","year":"2024","unstructured":"Matter, M. A. et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. Eur. Heart J. 45, 89\u2013103 (2024).","journal-title":"Eur. Heart J."},{"key":"1274_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrcardio.2015.2","volume":"12","author":"YF Hu","year":"2015","unstructured":"Hu, Y. F., Chen, Y. J., Lin, Y. J. & Chen, S. A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230\u2013243 (2015).","journal-title":"Nat. Rev. Cardiol."},{"key":"1274_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07166-8","volume":"15","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady, A. et al. Inflammation in atherosclerosis: pathophysiology and mechanisms. Cell Death Dis. 15, 817 (2024).","journal-title":"Cell Death Dis."},{"key":"1274_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/CIRCULATIONAHA.114.008788","volume":"131","author":"RA Frieler","year":"2015","unstructured":"Frieler, R. A. & Mortensen, R. M. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131, 1019\u20131030 (2015).","journal-title":"Circulation"},{"key":"1274_CR37","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","volume":"116","author":"DL Mann","year":"2015","unstructured":"Mann, D. L. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ. Res. 116, 1254\u20131268 (2015).","journal-title":"Circ. Res."},{"key":"1274_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110747","volume":"123","author":"XJ Zhang","year":"2023","unstructured":"Zhang, X. J. et al. Impact of inflammation and anti-inflammatory modalities on diabetic cardiomyopathy healing: from fundamental research to therapy. Int. Immunopharmacol. 123, 110747 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1274_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.695792","volume":"8","author":"T Salvatore","year":"2021","unstructured":"Salvatore, T. et al. The diabetic cardiomyopathy: the contributing pathophysiological mechanisms. Front. Med. 8, 695792 (2021).","journal-title":"Front. Med."},{"key":"1274_CR40","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1016\/j.ijcard.2013.07.150","volume":"168","author":"X Palomer","year":"2013","unstructured":"Palomer, X., Salvado, L., Barroso, E. & Vazquez-Carrera, M. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int. J. Cardiol. 168, 3160\u20133172 (2013).","journal-title":"Int. J. Cardiol."},{"key":"1274_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.4239\/wjd.v7.i13.271","volume":"7","author":"N Ridzuan","year":"2016","unstructured":"Ridzuan, N. et al. Preliminary study on overproduction of reactive oxygen species by neutrophils in diabetes mellitus. World J. Diabetes 7, 271\u2013278 (2016).","journal-title":"World J. Diabetes"},{"key":"1274_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","volume":"172","author":"A Faria","year":"2017","unstructured":"Faria, A. & Persaud, S. J. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacol. Ther. 172, 50\u201362 (2017).","journal-title":"Pharmacol. Ther."},{"key":"1274_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0849-1","volume":"14","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J. Transl. Med. 14, 109 (2016).","journal-title":"J. Transl. Med."},{"key":"1274_CR44","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/cvr\/cvx011","volume":"113","author":"G Frati","year":"2017","unstructured":"Frati, G. et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc. Res. 113, 378\u2013388 (2017).","journal-title":"Cardiovasc. Res."},{"key":"1274_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/20420188221083530","volume":"13","author":"P Ramesh","year":"2022","unstructured":"Ramesh, P., Yeo, J. L., Brady, E. M. & McCann, G. P. Role of inflammation in diabetic cardiomyopathy. Ther. Adv. Endocrinol. Metab. 13, 20420188221083530 (2022).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"1274_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.516","volume":"5","author":"L Zhao","year":"2024","unstructured":"Zhao, L. et al. Inflammation in diabetes complications: molecular mechanisms and therapeutic interventions. MedComm 5, e516 (2024).","journal-title":"MedComm"},{"key":"1274_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00455-6","volume":"6","author":"K Sun","year":"2021","unstructured":"Sun, K., Li, Y.-y. & Jin, J. A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct. Target. Ther. 6, 79 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1274_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1542208","volume":"16","author":"M Song","year":"2025","unstructured":"Song, M., Dai, H., Zhou, Q. & Meng, X. The immunology of diabetic cardiomyopathy. Front. Endocrinol. 16, 1542208 (2025).","journal-title":"Front. Endocrinol."},{"key":"1274_CR49","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3892\/mmr.2017.7033","volume":"16","author":"B Zhou","year":"2017","unstructured":"Zhou, B., Leng, Y., Lei, S. Q. & Xia, Z. Y. AMPK activation restores ischemic post-conditioning cardioprotection in STZ-induced type 1 diabetic rats: role of autophagy. Mol. Med. Rep. 16, 3648\u20133656 (2017).","journal-title":"Mol. Med. Rep."},{"key":"1274_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01303-9","volume":"20","author":"CD Cohen","year":"2021","unstructured":"Cohen, C. D. et al. Diastolic dysfunction in a pre-clinical model of diabetes is associated with changes in the cardiac non-myocyte cellular composition. Cardiovasc. Diabetol. 20, 116 (2021).","journal-title":"Cardiovasc. Diabetol."},{"key":"1274_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107759","volume":"26","author":"CD Cohen","year":"2023","unstructured":"Cohen, C. D. et al. Mapping the cellular and molecular landscape of cardiac non-myocytes in murine diabetic cardiomyopathy. iScience 26, 107759 (2023).","journal-title":"iScience"},{"key":"1274_CR52","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.yjmcc.2010.12.022","volume":"50","author":"XM Gao","year":"2011","unstructured":"Gao, X. M. et al. Deletion of macrophage migration inhibitory factor protects the heart from severe ischemia-reperfusion injury: a predominant role of anti-inflammation. J. Mol. Cell. Cardiol. 50, 991\u2013999 (2011).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1274_CR53","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1385\/CT:3:3:229","volume":"3","author":"WK Jones","year":"2003","unstructured":"Jones, W. K., Brown, M., Ren, X., He, S. & McGuinness, M. NF-\u03baB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc. Toxicol. 3, 229\u2013254 (2003).","journal-title":"Cardiovasc. Toxicol."},{"key":"1274_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/652097","volume":"2011","author":"O Lorenzo","year":"2011","unstructured":"Lorenzo, O. et al. Potential role of nuclear factor \u03baB in diabetic cardiomyopathy. Mediat. Inflamm. 2011, 652097 (2011).","journal-title":"Mediat. Inflamm."},{"key":"1274_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/A:1007133710837","volume":"212","author":"AR Brasier","year":"2000","unstructured":"Brasier, A. R., Jamaluddin, M., Han, Y., Patterson, C. & Runge, M. S. Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-\u03baB (NF-\u03baB) transcription factor. Mol. Cell. Biochem. 212, 155\u2013169 (2000).","journal-title":"Mol. Cell. Biochem."},{"key":"1274_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu, H., Lin, L., Zhang, Z., Zhang, H. & Hu, H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct. Target. Ther. 5, 209 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1274_CR57","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.8052854","volume":"265","author":"E Kopp","year":"1994","unstructured":"Kopp, E. & Ghosh, S. Inhibition of NF-\u03baB by sodium salicylate and aspirin. Science 265, 956\u2013959 (1994).","journal-title":"Science"},{"key":"1274_CR58","doi-asserted-by":"publisher","first-page":"H1036","DOI":"10.1152\/ajpheart.00340.2014","volume":"307","author":"CM Thomas","year":"2014","unstructured":"Thomas, C. M. et al. Cardiac-specific suppression of NF-\u03baB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am. J. Physiol. Heart Circ. Physiol. 307, H1036\u2013H1045 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1274_CR59","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2337\/db20-0357","volume":"70","author":"A Sharma","year":"2021","unstructured":"Sharma, A. et al. Specific NLRP3 inhibition protects against diabetes-associated atherosclerosis. Diabetes 70, 772\u2013787 (2021).","journal-title":"Diabetes"},{"key":"1274_CR60","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229\u2013265 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"1274_CR61","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/db12-0420","volume":"62","author":"HM Lee","year":"2013","unstructured":"Lee, H. M. et al. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 62, 194\u2013204 (2013).","journal-title":"Diabetes"},{"key":"1274_CR62","first-page":"442","volume":"16","author":"A Berbudi","year":"2020","unstructured":"Berbudi, A., Rahmadika, N., Tjahjadi, A. I. & Ruslami, R. Type 2 diabetes and its impact on the immune system. Curr. Diabetes Rev. 16, 442\u2013449 (2020).","journal-title":"Curr. Diabetes Rev."},{"key":"1274_CR63","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3790721","volume":"2022","author":"K Ding","year":"2022","unstructured":"Ding, K. et al. The role of NLRP3 inflammasome in diabetic cardiomyopathy and its therapeutic implications. Oxidative Med. Cell. Longev. 2022, 3790721 (2022).","journal-title":"Oxidative Med. Cell. Longev."},{"key":"1274_CR64","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2017-05-782102","volume":"130","author":"S Nazir","year":"2017","unstructured":"Nazir, S. et al. Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition. Blood 130, 2664\u20132677 (2017).","journal-title":"Blood"},{"key":"1274_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104771","volume":"9","author":"B Luo","year":"2014","unstructured":"Luo, B. et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 9, e104771 (2014).","journal-title":"PLoS ONE"},{"key":"1274_CR66","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.freeradbiomed.2024.12.049","volume":"228","author":"L Luo","year":"2025","unstructured":"Luo, L. et al. Lipotoxicity-induced upregulation of FIS1 exacerbates mitochondrial fragmentation and promotes NLRP3-dependent pyroptosis in diabetic cardiomyopathy. Free Radic. Biol. Med. 228, 183\u2013196 (2025).","journal-title":"Free Radic. Biol. Med."},{"key":"1274_CR67","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1253\/circj.CJ-10-1199","volume":"75","author":"Y Mano","year":"2011","unstructured":"Mano, Y. et al. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ. J. 75, 1717\u20131727 (2011).","journal-title":"Circ. J."},{"key":"1274_CR68","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00125-006-0385-2","volume":"49","author":"D Westermann","year":"2006","unstructured":"Westermann, D. et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49, 2507\u20132513 (2006).","journal-title":"Diabetologia"},{"key":"1274_CR69","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1161\/01.CIR.95.5.1247","volume":"95","author":"T Yokoyama","year":"1997","unstructured":"Yokoyama, T. et al. Tumor necrosis factor-\u03b1 provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95, 1247\u20131252 (1997).","journal-title":"Circulation"},{"key":"1274_CR70","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1161\/01.CIR.0000147233.10318.23","volume":"110","author":"M Sun","year":"2004","unstructured":"Sun, M. et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110, 3221\u20133228 (2004).","journal-title":"Circulation"},{"key":"1274_CR71","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/cvr\/cvq102","volume":"87","author":"CW Younce","year":"2010","unstructured":"Younce, C. W., Wang, K. & Kolattukudy, P. E. Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovasc. Res. 87, 665\u2013674 (2010).","journal-title":"Cardiovasc. Res."},{"key":"1274_CR72","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/0735-1097(95)00589-7","volume":"27","author":"G Torre-Amione","year":"1996","unstructured":"Torre-Amione, G. et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J. Am. Coll. Cardiol. 27, 1201\u20131206 (1996).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1274_CR73","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1067\/mhj.2001.113078","volume":"141","author":"RJ Raymond","year":"2001","unstructured":"Raymond, R. J., Dehmer, G. J., Theoharides, T. C. & Deliargyris, E. N. Elevated interleukin-6 levels in patients with asymptomatic left ventricular systolic dysfunction. Am. Heart J. 141, 435\u2013438 (2001).","journal-title":"Am. Heart J."},{"key":"1274_CR74","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.jacc.2007.12.048","volume":"51","author":"H Bahrami","year":"2008","unstructured":"Bahrami, H. et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J. Am. Coll. Cardiol. 51, 1775\u20131783 (2008).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1274_CR75","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.1073\/pnas.92.11.4862","volume":"92","author":"H Hirota","year":"1995","unstructured":"Hirota, H., Yoshida, K., Kishimoto, T. & Taga, T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl Acad. Sci. USA 92, 4862\u20134866 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1274_CR76","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1161\/01.CIR.0000057810.48709.F6","volume":"107","author":"RS Vasan","year":"2003","unstructured":"Vasan, R. S. et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107, 1486\u20131491 (2003).","journal-title":"Circulation"},{"key":"1274_CR77","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","volume":"75","author":"SP Murphy","year":"2020","unstructured":"Murphy, S. P., Kakkar, R., McCarthy, C. P. & Januzzi, J. L. Inflammation in heart failure: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 1324\u20131340 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1274_CR78","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11010-015-2483-2","volume":"408","author":"SK Gupta","year":"2015","unstructured":"Gupta, S. K. et al. Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocin-induced diabetic cardiomyopathy in rats. Mol. Cell. Biochem. 408, 63\u201372 (2015).","journal-title":"Mol. Cell. Biochem."},{"key":"1274_CR79","doi-asserted-by":"publisher","DOI":"10.2147\/ijicmr.S21679","author":"S Nunes","year":"2012","unstructured":"Nunes, S., Soares, E., Pereira, F. & Reis, F. The role of inflammation in diabetic cardiomyopathy. Int. J. Interferon Cytokine Mediat. Res. https:\/\/doi.org\/10.2147\/ijicmr.S21679 (2012).","journal-title":"Int. J. Interferon Cytokine Mediat. Res."},{"key":"1274_CR80","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.106.643585","volume":"115","author":"M Sun","year":"2007","unstructured":"Sun, M. et al. Tumor necrosis factor-\u03b1 mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115, 1398\u20131407 (2007).","journal-title":"Circulation"},{"key":"1274_CR81","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00395-007-0673-0","volume":"102","author":"D Westermann","year":"2007","unstructured":"Westermann, D. et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res. Cardiol. 102, 500\u2013507 (2007).","journal-title":"Basic Res. Cardiol."},{"key":"1274_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15978-3","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy. Nat. Commun. 11, 2148 (2020).","journal-title":"Nat. Commun."},{"key":"1274_CR83","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/aps.2014.127","volume":"36","author":"Z-w Liu","year":"2015","unstructured":"Liu, Z.-w et al. Matrine pretreatment improves cardiac function in rats with diabetic cardiomyopathy via suppressing ROS\/TLR-4 signaling pathway. Acta Pharmacol. Sin. 36, 323\u2013333 (2015).","journal-title":"Acta Pharmacol. Sin."},{"key":"1274_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-133","volume":"8","author":"Y Zhang","year":"2010","unstructured":"Zhang, Y. et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. J. Transl. Med. 8, 133 (2010).","journal-title":"J. Transl. Med."},{"key":"1274_CR85","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2337\/dc09-1799","volume":"33","author":"MR Dasu","year":"2010","unstructured":"Dasu, M. R., Devaraj, S., Park, S. & Jialal, I. Increased Toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 33, 861\u2013868 (2010).","journal-title":"Diabetes Care"},{"key":"1274_CR86","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.freeradbiomed.2022.01.020","volume":"181","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Elabela alleviates ferroptosis, myocardial remodeling, fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6\/STAT3\/GPX4 signaling. Free Radic. Biol. Med. 181, 130\u2013142 (2022).","journal-title":"Free Radic. Biol. Med."},{"key":"1274_CR87","doi-asserted-by":"publisher","first-page":"11188","DOI":"10.1080\/21655979.2021.2006978","volume":"12","author":"L Sun","year":"2021","unstructured":"Sun, L., Yang, Z., Zhang, J. & Wang, J. Isoliquiritigenin attenuates acute renal injury through suppressing oxidative stress, fibrosis and JAK2\/STAT3 pathway in streptozotocin-induced diabetic rats. Bioengineered 12, 11188\u201311200 (2021).","journal-title":"Bioengineered"},{"key":"1274_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112315","volume":"592","author":"C Shen","year":"2024","unstructured":"Shen, C. et al. Overexpression of MD1 ameliorates pathological myocardial remodeling in diabetic cardiomyopathy by TLR4\/STAT3 signaling pathway. Mol. Cell. Endocrinol. 592, 112315 (2024).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1274_CR89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.tcm.2006.03.001","volume":"16","author":"N Ouchi","year":"2006","unstructured":"Ouchi, N., Shibata, R. & Walsh, K. Cardioprotection by adiponectin. Trends Cardiovasc. Med. 16, 141\u2013146 (2006).","journal-title":"Trends Cardiovasc. Med."},{"key":"1274_CR90","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/545068","volume":"2015","author":"D Horakova","year":"2015","unstructured":"Horakova, D. et al. Total and high molecular weight adiponectin levels and prediction of cardiovascular risk in diabetic patients. Int. J. Endocrinol. 2015, 545068 (2015).","journal-title":"Int. J. Endocrinol."},{"key":"1274_CR91","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1210\/er.2005-0005","volume":"26","author":"T Kadowaki","year":"2005","unstructured":"Kadowaki, T. & Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev. 26, 439\u2013451 (2005).","journal-title":"Endocr. Rev."},{"key":"1274_CR92","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki, T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784\u20131792 (2006).","journal-title":"J. Clin. Invest."},{"key":"1274_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.12965\/jer.140100","volume":"10","author":"S Lee","year":"2014","unstructured":"Lee, S. & Kwak, H. B. Role of adiponectin in metabolic and cardiovascular disease. J. Exerc. Rehabil. 10, 54\u201359 (2014).","journal-title":"J. Exerc. Rehabil."},{"key":"1274_CR94","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3892\/etm.2014.1539","volume":"7","author":"J Li","year":"2014","unstructured":"Li, J., Su, S. & Zong, X. Analysis of the association between adiponectin, adiponectin receptor 1 and diabetic cardiomyopathy. Exp. Ther. Med. 7, 1023\u20131027 (2014).","journal-title":"Exp. Ther. Med."},{"key":"1274_CR95","doi-asserted-by":"publisher","first-page":"6821","DOI":"10.1016\/j.febslet.2005.11.019","volume":"579","author":"N Yamaguchi","year":"2005","unstructured":"Yamaguchi, N. et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett. 579, 6821\u20136826 (2005).","journal-title":"FEBS Lett."},{"key":"1274_CR96","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1161\/01.CIR.100.25.2473","volume":"100","author":"N Ouchi","year":"1999","unstructured":"Ouchi, N. et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100, 2473\u20132476 (1999).","journal-title":"Circulation"},{"key":"1274_CR97","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1161\/ATVBAHA.108.163303","volume":"28","author":"S Devaraj","year":"2008","unstructured":"Devaraj, S., Torok, N., Dasu, M. R., Samols, D. & Jialal, I. Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler. Thromb. Vasc. Biol. 28, 1368\u20131374 (2008).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1274_CR98","doi-asserted-by":"publisher","first-page":"E1436","DOI":"10.1152\/ajpendo.00445.2013","volume":"305","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Adiponectin inhibits oxidative\/nitrative stress during myocardial ischemia and reperfusion via PKA signaling. Am. J. Physiol. Endocrinol. Metab. 305, E1436\u2013E1443 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1274_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086404","volume":"9","author":"CM van Stijn","year":"2014","unstructured":"van Stijn, C. M., Kim, J., Barish, G. D., Tietge, U. J. & Tangirala, R. K. Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis. PLoS ONE 9, e86404 (2014).","journal-title":"PLoS ONE"},{"key":"1274_CR100","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature12656","volume":"503","author":"M Okada-Iwabu","year":"2013","unstructured":"Okada-Iwabu, M. et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503, 493\u2013499 (2013).","journal-title":"Nature"},{"key":"1274_CR101","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/nm1295","volume":"11","author":"R Shibata","year":"2005","unstructured":"Shibata, R. et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat. Med. 11, 1096\u20131103 (2005).","journal-title":"Nat. Med."},{"key":"1274_CR102","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0968-0896(01)00041-4","volume":"9","author":"NB Blatt","year":"2001","unstructured":"Blatt, N. B. & Glick, G. D. Signaling pathways and effector mechanisms pre-programmed cell death. Bioorg. Med. Chem. 9, 1371\u20131384 (2001).","journal-title":"Bioorg. Med. Chem."},{"key":"1274_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1242\/jcs.113.5.753","volume":"113","author":"J Wang","year":"2000","unstructured":"Wang, J. & Lenardo, M. J. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. J. Cell Sci. 113, 753\u2013757 (2000).","journal-title":"J. Cell Sci."},{"key":"1274_CR104","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacc.2003.09.026","volume":"43","author":"Y Chandrashekhar","year":"2004","unstructured":"Chandrashekhar, Y., Sen, S., Anway, R., Shuros, A. & Anand, I. Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J. Am. Coll. Cardiol. 43, 295\u2013301 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1274_CR105","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/01.RES.0000260203.55077.61","volume":"100","author":"S Merkle","year":"2007","unstructured":"Merkle, S. et al. A role for caspase-1 in heart failure. Circ. Res. 100, 645\u2013653 (2007).","journal-title":"Circ. Res."},{"key":"1274_CR106","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1161\/CIRCULATIONAHA.107.740233","volume":"117","author":"A Abbate","year":"2008","unstructured":"Abbate, A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117, 2670\u20132683 (2008).","journal-title":"Circulation"},{"key":"1274_CR107","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2007.12.040","volume":"132","author":"M Keller","year":"2008","unstructured":"Keller, M., R\u00fcegg, A., Werner, S. & Beer, H. D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818\u2013831 (2008).","journal-title":"Cell"},{"key":"1274_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70477-5","volume":"14","author":"W Zhou","year":"2024","unstructured":"Zhou, W. et al. Inhibition of caspase-1-dependent pyroptosis alleviates myocardial ischemia\/reperfusion injury during cardiopulmonary bypass (CPB) in type 2 diabetic rats. Sci. Rep. 14, 19420 (2024).","journal-title":"Sci. Rep."},{"key":"1274_CR109","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","volume":"18","author":"Y Huang","year":"2021","unstructured":"Huang, Y., Xu, W. & Zhou, R. NLRP3 inflammasome activation and cell death. Cell. Mol. Immunol. 18, 2114\u20132127 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"1274_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00114","volume":"9","author":"A Sharma","year":"2018","unstructured":"Sharma, A. et al. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. Front. Physiol. 9, 114 (2018).","journal-title":"Front. Physiol."},{"key":"1274_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175091","volume":"928","author":"H Li","year":"2022","unstructured":"Li, H. et al. Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome. Eur. J. Pharmacol. 928, 175091 (2022).","journal-title":"Eur. J. Pharmacol."},{"key":"1274_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.748183","volume":"9","author":"ZY Zhang","year":"2022","unstructured":"Zhang, Z. Y. et al. Glucose fluctuations aggravate myocardial fibrosis via the nuclear factor-\u03baB-mediated nucleotide-binding oligomerization domain-like receptor protein 3 inflammasome activation. Front. Cardiovasc. Med. 9, 748183 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"1274_CR113","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1111\/jcmm.16863","volume":"25","author":"C Nie","year":"2021","unstructured":"Nie, C. et al. Hydrogen gas inhalation ameliorates cardiac remodelling and fibrosis by regulating NLRP3 inflammasome in myocardial infarction rats. J. Cell. Mol. Med. 25, 8997\u20139010 (2021).","journal-title":"J. Cell. Mol. Med."},{"key":"1274_CR114","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.7150\/ijbs.29680","volume":"15","author":"F Yang","year":"2019","unstructured":"Yang, F. et al. Metformin inhibits the NLRP3 inflammasome via AMPK\/mTOR-dependent effects in diabetic cardiomyopathy. Int. J. Biol. Sci. 15, 1010\u20131019 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"1274_CR115","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2023.5252","volume":"51","author":"L Yang","year":"2023","unstructured":"Yang, L. et al. Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR-18a-3p\/Gsdmd pathway. Int. J. Mol. Med. 51, 49 (2023).","journal-title":"Int. J. Mol. Med."},{"key":"1274_CR116","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","volume":"126","author":"PM Ridker","year":"2012","unstructured":"Ridker, P. M. et al. Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126, 2739\u20132748 (2012).","journal-title":"Circulation"},{"key":"1274_CR117","doi-asserted-by":"publisher","first-page":"8023","DOI":"10.1007\/s00210-024-03152-1","volume":"397","author":"LM Mahmoud","year":"2024","unstructured":"Mahmoud, L. M. et al. Interleukin 1\u03b2 receptor blocker (anakinra) and regenerative stem cell therapy: two novel approaches effectively ameliorating diabetic cardiomyopathy. Naunyn Schmiedebergs Arch. Pharmacol. 397, 8023\u20138041 (2024).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"1274_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02501-x","volume":"23","author":"T Fu","year":"2024","unstructured":"Fu, T. et al. Lipoxin A4 improves cardiac remodeling and function in diabetes-associated cardiac dysfunction. Cardiovasc. Diabetol. 23, 413 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1274_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110657","volume":"106","author":"F Gonzalez-Herrera","year":"2023","unstructured":"Gonzalez-Herrera, F. et al. Lipoxin A4 prevents high glucose-induced inflammatory response in cardiac fibroblast through FOXO1 inhibition. Cell. Signal. 106, 110657 (2023).","journal-title":"Cell. Signal."},{"key":"1274_CR120","first-page":"231","volume":"7","author":"K Anderson","year":"2014","unstructured":"Anderson, K., Wherle, L., Park, M., Nelson, K. & Nguyen, L. Salsalate, an old, inexpensive drug with potential new indications: a review of the evidence from 3 recent studies. Am. Health Drug Benefits 7, 231\u2013235 (2014).","journal-title":"Am. Health Drug Benefits"},{"key":"1274_CR121","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00125-012-2819-3","volume":"56","author":"AB Goldfine","year":"2013","unstructured":"Goldfine, A. B. et al. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 56, 714\u2013723 (2013).","journal-title":"Diabetologia"},{"key":"1274_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.600427","volume":"8","author":"MC Nwadiugwu","year":"2020","unstructured":"Nwadiugwu, M. C. Inflammatory activities in type 2 diabetes patients with co-morbid angiopathies and exploring beneficial interventions: a systematic review. Front. Public Health 8, 600427 (2020).","journal-title":"Front. Public Health"},{"key":"1274_CR123","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1172\/JCI88884","volume":"127","author":"AB Goldfine","year":"2017","unstructured":"Goldfine, A. B. & Shoelson, S. E. Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. J. Clin. Invest. 127, 83\u201393 (2017).","journal-title":"J. Clin. Invest."},{"key":"1274_CR124","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jamacardio.2016.0605","volume":"1","author":"TH Hauser","year":"2016","unstructured":"Hauser, T. H. et al. Effect of targeting inflammation with salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins. JAMA Cardiol. 1, 413\u2013423 (2016).","journal-title":"JAMA Cardiol."},{"key":"1274_CR125","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4857","volume":"354","author":"A Arf\u00e8","year":"2016","unstructured":"Arf\u00e8, A. et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 354, i4857 (2016).","journal-title":"BMJ"},{"key":"1274_CR126","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ejheart.2008.07.013","volume":"10","author":"PA Scott","year":"2008","unstructured":"Scott, P. A., Kingsley, G. H. & Scott, D. L. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur. J. Heart Fail. 10, 1102\u20131107 (2008).","journal-title":"Eur. J. Heart Fail."},{"key":"1274_CR127","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jacc.2023.02.027","volume":"81","author":"A Holt","year":"2023","unstructured":"Holt, A. et al. Heart failure following anti-inflammatory medications in patients with type 2 diabetes mellitus. J. Am. Coll. Cardiol. 81, 1459\u20131470 (2023).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1274_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103267","volume":"9","author":"F Rolski","year":"2020","unstructured":"Rolski, F. & B\u0142yszczuk, P. Complexity of TNF-\u03b1 signaling in heart disease. J. Clin. Med. 9, 3267 (2020).","journal-title":"J. Clin. Med."},{"key":"1274_CR129","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/NEJM199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine, B., Kalman, J., Mayer, L., Fillit, H. M. & Packer, M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323, 236\u2013241 (1990).","journal-title":"N. Engl. J. Med."},{"key":"1274_CR130","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/01.RES.81.4.627","volume":"81","author":"T Kubota","year":"1997","unstructured":"Kubota, T. et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-\u03b1. Circ. Res. 81, 627\u2013635 (1997).","journal-title":"Circ. Res."},{"key":"1274_CR131","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/01.CIR.97.14.1382","volume":"97","author":"B Bozkurt","year":"1998","unstructured":"Bozkurt, B. et al. Pathophysiologically relevant concentrations of tumor necrosis factor-\u03b1 promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97, 1382\u20131391 (1998).","journal-title":"Circulation"},{"key":"1274_CR132","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","volume":"4","author":"AP Coletta","year":"2002","unstructured":"Coletta, A. P., Clark, A. L., Banarjee, P. & Cleland, J. G. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart Fail. 4, 559\u2013561 (2002).","journal-title":"Eur. J. Heart Fail."},{"key":"1274_CR133","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm, K. N. & Tyler, D. J. The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovasc. Drugs Ther. 34, 255\u2013269 (2020).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"1274_CR134","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/aps.2017.50","volume":"39","author":"W-j Fang","year":"2018","unstructured":"Fang, W. -j et al. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1\u03b1 deacetylation. Acta Pharmacol. Sin. 39, 59\u201373 (2018).","journal-title":"Acta Pharmacol. Sin."},{"key":"1274_CR135","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.4238\/2011.November.29.7","volume":"10","author":"AS Yar","year":"2011","unstructured":"Yar, A. S., Menevse, S. & Alp, E. The effects of resveratrol on cyclooxygenase-1 and -2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats. Genet. Mol. Res. 10, 2962\u20132975 (2011).","journal-title":"Genet. Mol. Res."},{"key":"1274_CR136","doi-asserted-by":"publisher","first-page":"H833","DOI":"10.1152\/ajpheart.00418.2009","volume":"298","author":"M Sulaiman","year":"2010","unstructured":"Sulaiman, M. et al. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 298, H833\u2013H843 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1274_CR137","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7051845","volume":"2020","author":"YJ Song","year":"2020","unstructured":"Song, Y. J., Zhong, C. B. & Wu, W. Resveratrol and diabetic cardiomyopathy: focusing on the protective signaling mechanisms. Oxidative Med. Cell. Longev. 2020, 7051845 (2020).","journal-title":"Oxidative Med. Cell. Longev."},{"key":"1274_CR138","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.mce.2015.05.034","volume":"412","author":"S Guo","year":"2015","unstructured":"Guo, S. et al. Resveratrol attenuates high glucose-induced oxidative stress and cardiomyocyte apoptosis through AMPK. Mol. Cell. Endocrinol. 412, 85\u201394 (2015).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1274_CR139","doi-asserted-by":"publisher","first-page":"H985","DOI":"10.1152\/ajpheart.00489.2010","volume":"299","author":"H Zhang","year":"2010","unstructured":"Zhang, H. et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative\/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am. J. Physiol. Heart Circ. Physiol. 299, H985\u2013H994 (2010).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1274_CR140","doi-asserted-by":"publisher","DOI":"10.2174\/0118761429353519250106115016","author":"X Li","year":"2025","unstructured":"Li, X. et al. Sirt1 regulates phenotypic transformation of diabetic cardiac fibroblasts through Akt\/A-SMA pathway. Curr. Mol. Pharmacol. https:\/\/doi.org\/10.2174\/0118761429353519250106115016 (2025).","journal-title":"Curr. Mol. Pharmacol."},{"key":"1274_CR141","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11010-016-2767-1","volume":"420","author":"R Saklani","year":"2016","unstructured":"Saklani, R. et al. Cardioprotective effects of rutin via alteration in TNF-\u03b1, CRP, and BNP levels coupled with antioxidant effect in STZ-induced diabetic rats. Mol. Cell. Biochem. 420, 65\u201372 (2016).","journal-title":"Mol. Cell. Biochem."},{"key":"1274_CR142","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1210\/en.2006-0728","volume":"147","author":"M Aragno","year":"2006","unstructured":"Aragno, M. et al. Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes. Endocrinology 147, 5967\u20135974 (2006).","journal-title":"Endocrinology"},{"key":"1274_CR143","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.cardiores.2004.05.001","volume":"63","author":"G Basta","year":"2004","unstructured":"Basta, G., Schmidt, A. M. & De Caterina, R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63, 582\u2013592 (2004).","journal-title":"Cardiovasc. Res."},{"key":"1274_CR144","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.biopha.2018.07.157","volume":"107","author":"B Giri","year":"2018","unstructured":"Giri, B. et al. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed. Pharmacother. 107, 306\u2013328 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"1274_CR145","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.acvd.2020.06.006","volume":"113","author":"S Battault","year":"2020","unstructured":"Battault, S. et al. Myocardial glucotoxicity: mechanisms and potential therapeutic targets. Arch. Cardiovasc. Dis. 113, 736\u2013748 (2020).","journal-title":"Arch. Cardiovasc. Dis."},{"key":"1274_CR146","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","volume":"117","author":"L van Heerebeek","year":"2008","unstructured":"van Heerebeek, L. et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117, 43\u201351 (2008).","journal-title":"Circulation"},{"key":"1274_CR147","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004872-200301000-00002","volume":"21","author":"D Aronson","year":"2003","unstructured":"Aronson, D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hypertens. 21, 3\u201312 (2003).","journal-title":"J. Hypertens."},{"key":"1274_CR148","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1161\/01.RES.87.3.179","volume":"87","author":"K Irani","year":"2000","unstructured":"Irani, K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 87, 179\u2013183 (2000).","journal-title":"Circ. Res."},{"key":"1274_CR149","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.RES.0000065620.39919.20","volume":"92","author":"R Candido","year":"2003","unstructured":"Candido, R. et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ. Res. 92, 785\u2013792 (2003).","journal-title":"Circ. Res."},{"key":"1274_CR150","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2741\/3315","volume":"14","author":"L Lin","year":"2009","unstructured":"Lin, L., Park, S. & Lakatta, E. G. RAGE signaling in inflammation and arterial aging. Front. Biosci. 14, 1403\u20131413 (2009).","journal-title":"Front. Biosci."},{"key":"1274_CR151","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.diabet.2018.07.003","volume":"45","author":"M Joubert","year":"2018","unstructured":"Joubert, M., Manrique, A., Cariou, B. & Prieur, X. Diabetes-related cardiomyopathy: the sweet story of glucose overload from epidemiology to cellular pathways. Diabetes Metab. 45, 238\u2013247 (2018).","journal-title":"Diabetes Metab."},{"key":"1274_CR152","doi-asserted-by":"publisher","first-page":"E323","DOI":"10.1152\/ajpendo.00024.2008","volume":"295","author":"C Tikellis","year":"2008","unstructured":"Tikellis, C. et al. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. Am. J. Physiol. Endocrinol. Metab. 295, E323\u2013E330 (2008).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1274_CR153","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.bbalip.2009.09.023","volume":"1801","author":"AR Wende","year":"2010","unstructured":"Wende, A. R. & Abel, E. D. Lipotoxicity in the heart. Biochim. Biophys. Acta 1801, 311\u2013319 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"1274_CR154","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.bbalip.2016.03.020","volume":"1861","author":"A Fukushima","year":"2016","unstructured":"Fukushima, A. & Lopaschuk, G. D. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1861, 1525\u20131534 (2016).","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"1274_CR155","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.coph.2020.08.015","volume":"54","author":"S Nirengi","year":"2020","unstructured":"Nirengi, S., Peres Valgas da Silva, C. & Stanford, K. I. Disruption of energy utilization in diabetic cardiomyopathy; a mini review. Curr. Opin. Pharmacol. 54, 82\u201390 (2020).","journal-title":"Curr. Opin. Pharmacol."},{"key":"1274_CR156","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1194\/jlr.M600299-JLR200","volume":"47","author":"NM Borradaile","year":"2006","unstructured":"Borradaile, N. M. et al. Disruption of endoplasmic reticulum structure and integrity in lipotoxic cell death. J. Lipid Res. 47, 2726\u20132737 (2006).","journal-title":"J. Lipid Res."},{"key":"1274_CR157","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1194\/jlr.R067595","volume":"57","author":"J Han","year":"2016","unstructured":"Han, J. & Kaufman, R. J. The role of ER stress in lipid metabolism and lipotoxicity. J. Lipid Res. 57, 1329\u20131338 (2016).","journal-title":"J. Lipid Res."},{"key":"1274_CR158","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6430342","volume":"2022","author":"J Liu","year":"2022","unstructured":"Liu, J., He, X., Zheng, S., Zhu, A. & Wang, J. The mitochondrial unfolded protein response: a novel protective pathway targeting cardiomyocytes. Oxidative Med. Cell. Longev. 2022, 6430342 (2022).","journal-title":"Oxidative Med. Cell. Longev."},{"key":"1274_CR159","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1586\/14779072.2014.891939","volume":"12","author":"JR Ussher","year":"2014","unstructured":"Ussher, J. R. The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. Expert Rev. Cardiovasc. Ther. 12, 345\u2013358 (2014).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"1274_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/jpps.2024.12568","volume":"27","author":"M Nakamura","year":"2024","unstructured":"Nakamura, M. Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy. J. Pharm. Pharm. Sci. 27, 12568 (2024).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"1274_CR161","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108008","volume":"232","author":"A Sharma","year":"2022","unstructured":"Sharma, A., Mah, M., Ritchie, R. H. & De Blasio, M. J. The adiponectin signalling pathway \u2014 a therapeutic target for the cardiac complications of type 2 diabetes. Pharmacol. Ther. 232, 108008 (2022).","journal-title":"Pharmacol. Ther."},{"key":"1274_CR162","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1073\/pnas.97.4.1784","volume":"97","author":"YT Zhou","year":"2000","unstructured":"Zhou, Y. T. et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc. Natl Acad. Sci. USA 97, 1784\u20131789 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1274_CR163","doi-asserted-by":"publisher","first-page":"E1341","DOI":"10.1152\/ajpendo.00095.2006","volume":"291","author":"SM Turpin","year":"2006","unstructured":"Turpin, S. M., Lancaster, G. I., Darby, I., Febbraio, M. A. & Watt, M. J. Apoptosis in skeletal muscle myotubes is induced by ceramides and is positively related to insulin resistance. Am. J. Physiol. Endocrinol. Metab. 291, E1341\u2013E1350 (2006).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1274_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-0339-2","author":"Y Tan","year":"2020","unstructured":"Tan, Y. et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat. Rev. Cardiol. https:\/\/doi.org\/10.1038\/s41569-020-0339-2 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"1274_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113948","volume":"177","author":"S Mangali","year":"2020","unstructured":"Mangali, S. et al. Upregulation of PKR pathway mediates glucolipotoxicity induced diabetic cardiomyopathy in vivo in Wistar rats and in vitro in cultured cardiomyocytes. Biochem. Pharmacol. 177, 113948 (2020).","journal-title":"Biochem. Pharmacol."},{"key":"1274_CR166","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1172\/JCI10947","volume":"107","author":"H-C Chiu","year":"2001","unstructured":"Chiu, H.-C. et al. Novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107, 813\u2013822 (2001).","journal-title":"J. Clin. Invest."},{"key":"1274_CR167","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/JLB.3HI0219-045RR","volume":"106","author":"G Kalugotla","year":"2019","unstructured":"Kalugotla, G. et al. Frontline Science: Acyl-CoA synthetase 1 exacerbates lipotoxic inflammasome activation in primary macrophages. J. Leukoc. Biol. 106, 803\u2013814 (2019).","journal-title":"J. Leukoc. Biol."},{"key":"1274_CR168","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/157340308783565429","volume":"4","author":"A Chabowski","year":"2008","unstructured":"Chabowski, A., G\u00f3rski, J., Glatz, J. F., JJ, P. L. & Bonen, A. Protein-mediated fatty acid uptake in the heart. Curr. Cardiol. Rev. 4, 12\u201321 (2008).","journal-title":"Curr. Cardiol. Rev."},{"key":"1274_CR169","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/CIRCRESAHA.119.315833","volume":"125","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. Mitochondrial metabolic reprogramming by CD36 signaling drives macrophage inflammatory responses. Circ. Res. 125, 1087\u20131102 (2019).","journal-title":"Circ. Res."},{"key":"1274_CR170","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00125-012-2495-3","volume":"55","author":"K Huynh","year":"2012","unstructured":"Huynh, K. et al. Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db\/db mouse model of type 2 diabetes. Diabetologia 55, 1544\u20131553 (2012).","journal-title":"Diabetologia"},{"key":"1274_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2025.101345","volume":"10","author":"AM Parker","year":"2025","unstructured":"Parker, A. M. et al. Precision Medicine: Therapeutically targeting mitochondrial alterations in heart failure. JACC Basic Transl. Sci. 10, 101345 (2025).","journal-title":"JACC Basic Transl. Sci."},{"key":"1274_CR172","volume":"13","author":"AM Parker","year":"2025","unstructured":"Parker, A. M. et al. MitoQ protects against oxidative stress-induced mitochondrial dysregulation in human cardiomyocytes. J. Mol. Cell. Cardiol. Plus 13, 100469 (2025).","journal-title":"J. Mol. Cell. Cardiol. Plus"},{"key":"1274_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.672252","volume":"12","author":"AM Parker","year":"2021","unstructured":"Parker, A. M. et al. Characterisation of the myocardial mitochondria structural and functional phenotype in a murine model of diabetic cardiomyopathy. Front. Physiol. 12, 672252 (2021).","journal-title":"Front. Physiol."},{"key":"1274_CR174","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","volume":"102","author":"JA Kim","year":"2008","unstructured":"Kim, J. A., Wei, Y. & Sowers, J. R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res. 102, 401\u2013414 (2008).","journal-title":"Circ. Res."},{"key":"1274_CR175","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/ars.2009.2531","volume":"12","author":"WI Sivitz","year":"2010","unstructured":"Sivitz, W. I. & Yorek, M. A. Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antioxid. Redox Signal. 12, 537\u2013577 (2010).","journal-title":"Antioxid. Redox Signal."},{"key":"1274_CR176","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P Delerive","year":"1999","unstructured":"Delerive, P. et al. Peroxisome proliferator-activated receptor \u03b1 negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-\u03baB and AP-1. J. Biol. Chem. 274, 32048\u201332054 (1999).","journal-title":"J. Biol. Chem."},{"key":"1274_CR177","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.yjmcc.2003.11.004","volume":"36","author":"QN Diep","year":"2004","unstructured":"Diep, Q. N. et al. PPAR\u03b1 activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J. Mol. Cell. Cardiol. 36, 295\u2013304 (2004).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1274_CR178","doi-asserted-by":"publisher","first-page":"284S","DOI":"10.1042\/CS103S284S","volume":"103","author":"T Ogata","year":"2002","unstructured":"Ogata, T. et al. Stimulation of peroxisome-proliferator-activated receptor \u03b1 (PPAR \u03b1) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin. Sci. 103, 284S\u2013288S (2002).","journal-title":"Clin. Sci."},{"key":"1274_CR179","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1210\/jc.2009-1487","volume":"95","author":"R Belfort","year":"2010","unstructured":"Belfort, R., Berria, R., Cornell, J. & Cusi, K. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J. Clin. Endocrinol. Metab. 95, 829\u2013836 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1274_CR180","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cmet.2005.03.002","volume":"1","author":"Z Arany","year":"2005","unstructured":"Arany, Z. et al. Transcriptional coactivator PGC-1\u03b1 controls the energy state and contractile function of cardiac muscle. Cell Metab. 1, 259\u2013271 (2005).","journal-title":"Cell Metab."},{"key":"1274_CR181","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yexcr.2018.10.003","volume":"373","author":"M Waldman","year":"2018","unstructured":"Waldman, M. et al. PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1\u03b1 axis. Exp. Cell Res. 373, 112\u2013118 (2018).","journal-title":"Exp. Cell Res."},{"key":"1274_CR182","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/cvr\/cvn327","volume":"81","author":"X Palomer","year":"2009","unstructured":"Palomer, X. et al. TNF-\u03b1 reduces PGC-1\u03b1 expression through NF-\u03baB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc. Res. 81, 703\u2013712 (2009).","journal-title":"Cardiovasc. Res."},{"key":"1274_CR183","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1452696","volume":"2020","author":"S Rius-P\u00e9rez","year":"2020","unstructured":"Rius-P\u00e9rez, S., Torres-Cuevas, I., Mill\u00e1n, I., Ortega, \u00c1L. & P\u00e9rez, S. PGC-1\u03b1, inflammation, and oxidative stress: an integrative view in metabolism. Oxidative Med. Cell. Longev. 2020, 1452696 (2020).","journal-title":"Oxidative Med. Cell. Longev."},{"key":"1274_CR184","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/cvr\/cvq376","volume":"90","author":"A Planavila","year":"2011","unstructured":"Planavila, A., Iglesias, R., Giralt, M. & Villarroya, F. Sirt1 acts in association with PPAR\u03b1 to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc. Res. 90, 276\u2013284 (2011).","journal-title":"Cardiovasc. Res."},{"key":"1274_CR185","doi-asserted-by":"publisher","first-page":"9793","DOI":"10.1073\/pnas.0802917105","volume":"105","author":"PT Pfluger","year":"2008","unstructured":"Pfluger, P. T., Herranz, D., Velasco-Miguel, S., Serrano, M. & Tsch\u00f6p, M. H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl Acad. Sci. USA 105, 9793\u20139798 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1274_CR186","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tem.2011.05.001","volume":"22","author":"S Gray","year":"2011","unstructured":"Gray, S. & Kim, J. K. New insights into insulin resistance in the diabetic heart. Trends Endocrinol. Metab. 22, 394\u2013403 (2011).","journal-title":"Trends Endocrinol. Metab."},{"key":"1274_CR187","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.bbamcr.2012.08.009","volume":"1833","author":"C Montessuit","year":"2013","unstructured":"Montessuit, C. & Lerch, R. Regulation and dysregulation of glucose transport in cardiomyocytes. Biochim. Biophys. Acta Mol. Cell Res. 1833, 848\u2013856 (2013).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1274_CR188","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/eurheartj\/ehp396","volume":"31","author":"SA Cook","year":"2010","unstructured":"Cook, S. A. et al. Abnormal myocardial insulin signalling in type 2 diabetes and left-ventricular dysfunction. Eur. Heart J. 31, 100\u2013111 (2010).","journal-title":"Eur. Heart J."},{"key":"1274_CR189","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119748","volume":"1871","author":"O Simsek Papur","year":"2024","unstructured":"Simsek Papur, O., Glatz, J. F. C. & Luiken, J. J. F. P. Protein kinase-D1 and downstream signaling mechanisms involved in GLUT4 translocation in cardiac muscle. Biochim. Biophys. Acta Mol. Cell Res. 1871, 119748 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"1274_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00041","volume":"7","author":"H D\u00f6ppler","year":"2017","unstructured":"D\u00f6ppler, H. & Storz, P. Mitochondrial and oxidative stress-mediated activation of protein kinase d1 and its importance in pancreatic cancer. Front. Oncol. 7, 41 (2017).","journal-title":"Front. Oncol."},{"key":"1274_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.apsb.2015.06.002","volume":"6","author":"DG Hardie","year":"2016","unstructured":"Hardie, D. G. Regulation of AMP-activated protein kinase by natural and synthetic activators. Acta Pharm. Sin. B 6, 1\u201319 (2016).","journal-title":"Acta Pharm. Sin. B"},{"key":"1274_CR192","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2217\/clp.09.43","volume":"4","author":"G Kewalramani","year":"2009","unstructured":"Kewalramani, G. & Rodrigues, B. AMP-activated protein kinase in the heart: role in cardiac glucose and fatty acid metabolism. Clin. Lipidol. 4, 643\u2013661 (2009).","journal-title":"Clin. Lipidol."},{"key":"1274_CR193","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1161\/01.RES.0000258446.23525.37","volume":"100","author":"M Arad","year":"2007","unstructured":"Arad, M., Seidman, C. E. & Seidman, J. G. AMP-activated protein kinase in the heart: role during health and disease. Circ. Res. 100, 474\u2013488 (2007).","journal-title":"Circ. Res."},{"key":"1274_CR194","doi-asserted-by":"publisher","first-page":"15983","DOI":"10.1073\/pnas.252625599","volume":"99","author":"H Zong","year":"2002","unstructured":"Zong, H. et al. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc. Natl Acad. Sci. USA 99, 15983\u201315987 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1274_CR195","doi-asserted-by":"publisher","first-page":"H1120","DOI":"10.1152\/ajpheart.00210.2014","volume":"307","author":"M Balteau","year":"2014","unstructured":"Balteau, M. et al. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 307, H1120\u2013H1133 (2014).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1274_CR196","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1210\/en.2013-2011","volume":"155","author":"GM Qi","year":"2014","unstructured":"Qi, G. M., Jia, L. X., Li, Y. L., Li, H. H. & Du, J. Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy. Endocrinology 155, 2254\u20132265 (2014).","journal-title":"Endocrinology"},{"key":"1274_CR197","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/jcb.21197","volume":"100","author":"HL Li","year":"2007","unstructured":"Li, H. L. et al. Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy. J. Cell. Biochem. 100, 1086\u20131099 (2007).","journal-title":"J. Cell. Biochem."},{"key":"1274_CR198","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10557-013-6498-1","volume":"28","author":"B Luo","year":"2014","unstructured":"Luo, B. et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc. Drugs Ther. 28, 33\u201343 (2014).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"1274_CR199","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4239\/wjd.v14.i12.1849","volume":"14","author":"XM Song","year":"2023","unstructured":"Song, X. M. et al. Atorvastatin ameliorated myocardial fibrosis in db\/db mice by inhibiting oxidative stress and modulating macrophage polarization. World J. Diabetes 14, 1849\u20131861 (2023).","journal-title":"World J. Diabetes"},{"key":"1274_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.634900","volume":"9","author":"W Jia","year":"2021","unstructured":"Jia, W. et al. Combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in type 2 diabetic mice. Front. Cell Dev. Biol. 9, 634900 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1274_CR201","volume":"11","author":"T Jakob","year":"2016","unstructured":"Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-Gonz\u00e1lez, I. & Briel, M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst. Rev. 11, CD009753 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1274_CR202","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MOL.0b013e32833c1e74","volume":"21","author":"AS Wierzbicki","year":"2010","unstructured":"Wierzbicki, A. S. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr. Opin. Lipidol. 21, 352\u2013358 (2010).","journal-title":"Curr. Opin. Lipidol."},{"key":"1274_CR203","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2165\/11208090-000000000-00000","volume":"71","author":"K McKeage","year":"2011","unstructured":"McKeage, K. & Keating, G. M. Fenofibrate: a review of its use in dyslipidaemia. Drugs 71, 1917\u20131946 (2011).","journal-title":"Drugs"},{"key":"1274_CR204","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02417-6","volume":"23","author":"J Park","year":"2024","unstructured":"Park, J. et al. Cardiometabolic benefits of fenofibrate in heart failure related to obesity and diabetes. Cardiovasc. Diabetol. 23, 343 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1274_CR205","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny, H. C. & Abel, E. D. Heart failure in type 2 diabetes mellitus. Circ. Res. 124, 121\u2013141 (2019).","journal-title":"Circ. Res."},{"key":"1274_CR206","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1089\/dia.2006.8.18","volume":"8","author":"KA Deans","year":"2006","unstructured":"Deans, K. A. & Sattar, N. \u201cAnti-inflammatory\u201d drugs and their effects on type 2 diabetes. Diabetes Technol. Ther. 8, 18\u201327 (2006).","journal-title":"Diabetes Technol. Ther."},{"key":"1274_CR207","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cardfail.2006.10.013","volume":"13","author":"M White","year":"2007","unstructured":"White, M. et al. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J. Card. Fail. 13, 86\u201394 (2007).","journal-title":"J. Card. Fail."},{"key":"1274_CR208","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/JOE-21-0194","volume":"251","author":"R Krist\u00f3fi","year":"2021","unstructured":"Krist\u00f3fi, R. & Eriksson, J. W. Metformin as an anti-inflammatory agent: a short review. J. Endocrinol. 251, R11\u2013R22 (2021).","journal-title":"J. Endocrinol."},{"key":"1274_CR209","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.2147\/JIR.S436147","volume":"16","author":"H Lin","year":"2023","unstructured":"Lin, H., Haiyong, A., Guanghua, G. & Liu, M. The role and mechanism of metformin in inflammatory diseases. J. Inflamm. Res. 16, 5545\u20135564 (2023).","journal-title":"J. Inflamm. Res."},{"key":"1274_CR210","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1021\/acsptsci.1c00167","volume":"4","author":"M Ala","year":"2021","unstructured":"Ala, M. & Ala, M. Metformin for cardiovascular protection, inflammatory bowel disease, osteoporosis, periodontitis, polycystic ovarian syndrome, neurodegeneration, cancer, inflammation and senescence: what is next? ACS Pharmacol. Transl. Sci. 4, 1747\u20131770 (2021).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"1274_CR211","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.2337\/db10-0351","volume":"60","author":"Z Xie","year":"2011","unstructured":"Xie, Z. et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60, 1770\u20131778 (2011).","journal-title":"Diabetes"},{"key":"1274_CR212","first-page":"911","volume":"11","author":"H Gao","year":"2019","unstructured":"Gao, H. et al. Phasic change and apoptosis regulation of JAK2\/STAT3 pathway in a type 2 diabetic rat model. Am. J. Transl. Res. 11, 911\u2013930 (2019).","journal-title":"Am. J. Transl. Res."},{"key":"1274_CR213","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2337\/diab.41.6.766","volume":"41","author":"SC Cramer","year":"1992","unstructured":"Cramer, S. C., Pardridge, W. M., Hirayama, B. A. & Wright, E. M. Colocalization of GLUT2 glucose transporter, sodium\/glucose cotransporter, and \u03b3-glutamyl transpeptidase in rat kidney with double-peroxidase immunocytochemistry. Diabetes 41, 766\u2013770 (1992).","journal-title":"Diabetes"},{"key":"1274_CR214","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1111\/bph.15820","volume":"180","author":"A Sharma","year":"2023","unstructured":"Sharma, A., De Blasio, M. J. & Ritchie, R. H. Current challenges in the treatment of cardiac fibrosis: recent insights into the sex-specific differences of glucose-lowering therapies on the diabetic heart: IUPHAR Review 33. Br. J. Pharmacol. 180, 2916\u20132933 (2023).","journal-title":"Br. J. Pharmacol."},{"key":"1274_CR215","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie, M. R. & Fisher, M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat. Rev. Cardiol. 17, 761\u2013772 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"1274_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107723","volume":"34","author":"N Katsiki","year":"2020","unstructured":"Katsiki, N. & Ferrannini, E. Anti-inflammatory properties of antidiabetic drugs: a \u201cpromised land\u201d in the COVID-19 era? J. Diabetes Complicat. 34, 107723 (2020).","journal-title":"J. Diabetes Complicat."},{"key":"1274_CR217","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li, C. et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc. Diabetol. 18, 15 (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"1274_CR218","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1122494","volume":"2022","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxidative Med. Cell. Longev. 2022, 1122494 (2022).","journal-title":"Oxidative Med. Cell. Longev."},{"key":"1274_CR219","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31, 119\u2013132 (2017).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"1274_CR220","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4158\/EP.13.5.444","volume":"13","author":"P Viswanathan","year":"2007","unstructured":"Viswanathan, P. et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr. Pract. 13, 444\u2013450 (2007).","journal-title":"Endocr. Pract."},{"key":"1274_CR221","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1210\/jc.2011-1508","volume":"97","author":"A Chaudhuri","year":"2012","unstructured":"Chaudhuri, A. et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97, 198\u2013207 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1274_CR222","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","volume":"111","author":"M Tate","year":"2016","unstructured":"Tate, M., Robinson, E., Green, B. D., McDermott, B. J. & Grieve, D. J. Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res. Cardiol. 111, 1 (2016).","journal-title":"Basic Res. Cardiol."},{"key":"1274_CR223","first-page":"1358","volume":"24","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Wang, X., Yang, L., Yang, L. & Ma, H. Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt1\/AMPK signaling. Iran. J. Basic Med. Sci. 24, 1358\u20131365 (2021).","journal-title":"Iran. J. Basic Med. Sci."},{"key":"1274_CR224","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114573","volume":"43","author":"JSF Chan","year":"2024","unstructured":"Chan, J. S. F. et al. Growth differentiation factor 15 alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy. Cell Rep. 43, 114573 (2024).","journal-title":"Cell Rep."},{"key":"1274_CR225","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1210\/jc.2012-1544","volume":"97","author":"A Makdissi","year":"2012","unstructured":"Makdissi, A. et al. Sitagliptin exerts an antinflammatory action. J. Clin. Endocrinol. Metab. 97, 3333\u20133341 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1274_CR226","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopha.2018.07.126","volume":"107","author":"NT Al-Damry","year":"2018","unstructured":"Al-Damry, N. T. et al. Sitagliptin attenuates myocardial apoptosis via activating LKB-1\/AMPK\/Akt pathway and suppressing the activity of GSK-3\u03b2 and p38\u03b1\/MAPK in a rat model of diabetic cardiomyopathy. Biomed. Pharmacother. 107, 347\u2013358 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"1274_CR227","doi-asserted-by":"publisher","first-page":"724","DOI":"10.4239\/wjd.v15.i4.724","volume":"15","author":"GL Zhang","year":"2024","unstructured":"Zhang, G. L. et al. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J. Diabetes 15, 724\u2013734 (2024).","journal-title":"World J. Diabetes"},{"key":"1274_CR228","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00592-011-0278-9","volume":"48","author":"E Hopps","year":"2011","unstructured":"Hopps, E., Canino, B. & Caimi, G. Effects of exercise on inflammation markers in type 2 diabetic subjects. Acta Diabetol. 48, 183\u2013189 (2011).","journal-title":"Acta Diabetol."},{"key":"1274_CR229","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23427","volume":"10","author":"S Shabab","year":"2024","unstructured":"Shabab, S., Mahmoudabady, M., Gholamnezhad, Z., Fouladi, M. & Asghari, A. A. Diabetic cardiomyopathy in rats was attenuated by endurance exercise through the inhibition of inflammation and apoptosis. Heliyon 10, e23427 (2024).","journal-title":"Heliyon"},{"key":"1274_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01286","volume":"10","author":"X Chen","year":"2019","unstructured":"Chen, X. et al. Aerobic exercise ameliorates myocardial inflammation, fibrosis and apoptosis in high-fat-diet rats by inhibiting P2X7 purinergic receptors. Front. Physiol. 10, 1286 (2019).","journal-title":"Front. Physiol."},{"key":"1274_CR231","doi-asserted-by":"publisher","DOI":"10.3390\/antiox8120638","volume":"8","author":"S Kar","year":"2019","unstructured":"Kar, S. et al. Exercise training promotes cardiac hydrogen sulfide biosynthesis and mitigates pyroptosis to prevent high-fat diet-induced diabetic cardiomyopathy. Antioxidants 8, 638 (2019).","journal-title":"Antioxidants"},{"key":"1274_CR232","doi-asserted-by":"publisher","DOI":"10.3390\/nu14142956","volume":"14","author":"M Finicelli","year":"2022","unstructured":"Finicelli, M., Di Salle, A., Galderisi, U. & Peluso, G. The Mediterranean diet: an update of the clinical trials. Nutrients 14, 2956 (2022).","journal-title":"Nutrients"},{"key":"1274_CR233","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41569-024-01061-7","volume":"22","author":"NJ Pagidipati","year":"2025","unstructured":"Pagidipati, N. J., Taub, P. R., Ostfeld, R. J. & Kirkpatrick, C. F. Dietary patterns to promote cardiometabolic health. Nat. Rev. Cardiol. 22, 38\u201346 (2025).","journal-title":"Nat. Rev. Cardiol."},{"key":"1274_CR234","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.lfs.2012.09.012","volume":"91","author":"M Scotece","year":"2012","unstructured":"Scotece, M. et al. Further evidence for the anti-inflammatory activity of oleocanthal: inhibition of MIP-1\u03b1 and IL-6 in J774 macrophages and in ATDC5 chondrocytes. Life Sci. 91, 1229\u20131235 (2012).","journal-title":"Life Sci."},{"key":"1274_CR235","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-11-33","volume":"11","author":"YF Ni","year":"2010","unstructured":"Ni, Y. F. et al. Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice. Respir. Res. 11, 33 (2010).","journal-title":"Respir. Res."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01274-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01274-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01274-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:02:38Z","timestamp":1789128158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-026-01274-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":235,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1038\/s41569-026-01274-y","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}